Evamist.com

Simple spray application that women find easy to use

In an experience study, women ranked Evamist 8.3 out of 9 for ease-of-use, with 9 being very easy to use^*1
In the same study, convenience was the #1 Evamist attribute women found important^†1

3 out of 4 women reported that Evamist spray was more convenient than their previous patch therapy^‡1

Fits easily into her daily routine

Once-daily application with 1, 2, or 3 sprays to a small area of the inner forearm²
Dries quickly so patients can apply and go^§1
No need to touch medication or wash hands following application²

Evamist offers the flexibility of dosing adjustments when needed

No need to issue a new prescription initially for dosing adjustments²

» References

As reported in an experience study of 247 women using Evamist.¹

†

In an experience study of 247 women using Evamist, the majority of women ranked convenience higher in importance than any other Evamist attribute.¹

‡

As reported in an experience study of 247 women using Evamist, 53 of whom had previously used estrogen patch therapy.¹

Dries in a median of 67 seconds. Patients should let spray dry for at least 2 minutes before dressing, and at least 30 minutes before washing.^1,2

Important Safety Information

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER, PROBABLE DEMENTIA and UNINTENTIONAL SECONDARY EXPOSURE TO ESTROGEN

See full prescribing information for complete boxed warning

Estrogen-Alone Therapy

•	There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
•	Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
•	The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
•	The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Estrogen Plus Progestin Therapy

•	Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
•	The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism, and myocardial infarction
•	The WHI estrogen plus progestin study reported increased risks of invasive breast cancer
•	The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Estrogens with or without progestins should be prescribed at the lowest effective doses for the shortest duration consistent with the treatment goals for the individual woman.

Unintentional Secondary Exposure

Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional secondary exposure to Evamist by women using this product. In most cases, the condition resolved with removal of Evamist exposure. Women should ensure that children do not come into contact with the site(s) where Evamist is applied. Healthcare providers should advise patients to strictly adhere to recommended instructions for use.

Evamist is an estrogen indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Evamist should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or history of these conditions; active or recent arterial thromboembolic disease; liver dysfunction or disease; or known or suspected pregnancy.

In a clinical trial with Evamist the most common side effects were headache, breast tenderness, nipple pain, nausea, back pain and nasopharyngitis

Please see full prescribing information for Evamist, including boxed warnings.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.